I had done research on "Scope of Individualistic treatment with Serially Succussed and Diluted Drugs in treating Pre-diabetic condition: an Open-label Exploratory trial – in search of Prevention of Diabetes" and this was got awarded in Short Term Studentship in Homeopathy (STSH) 2014 by Central Council for Research in Homeopathy (CCRH), Ministry of AYUSH, Govt. of India.

1. Sutanu Patra
4th BHMS (2017-18), MHMCH, Midnapore, West Bengal;
STSH 2014 Young Scientist Scholar (CCRH, Ministry of AYUSH,
Govt. Of India);
CHRF (NIE Chennai, ICMR); CBMN.Tech (IIT Roorkee)

2. Pre-diabetes is the medical stage
in which not all of the symptoms
required to label a person as
diabetic are present, but blood
sugar is abnormally high.
This stage is often referred to as
the “grey area”. This condition is
also referred as Also known as
Chemical diabetes, Potential
diabetes, Sugar deregulation or
Borderline diabetes.
Reference:
Jellinger, Paul S. "What You Need to Know about Prediabetes. Power of Prevention, American College of Endocrinology. Vol. 1,
issue 2, May 2009. Available from: http://www.powerofprevention.com/

3. 5-10% of people per year with
pre-diabetes will progress to type-
II Diabetes Mellitus. Prevalence of
pre-diabetes is increasing
worldwide and experts have
projected that more than 470
million people will have pre-
diabetes by 2030.
Need of the Research
Reference:
Nichols GA, Hillier TA, Brown JB (2007). "Progression from Newly Acquired Impaired Fasting Glucose to Type 2
Diabetes". Diabetes Care 30 (2): 228–233.

4. Signalling Pathway of Pre-DM
Pre-diabetes

5. Research Papers on Cause of Pre-diabetes
Reference:
Thomas A VanderJagt, Monica H Neugebauer, Marilee Morgan, Donald W Bowden,
Vallabh O Shah: Epigenetic profiles of pre-diabetes transitioning to type 2 diabetes
and nephropathy. World J Diabetes 10; 6(9): 1113-1121. 2015 August. ISSN 1948-
9358 (online)
Reference:
Louise D. Zheng, Leah E. Linarelli, Joseph Brooke, Cayleen Smith, Sarah S. Wall, Mark H.
Greenawald, Richard W. Seidel, Paul A. Estabrooks, Fabio A. Almeida, Zhiyong Cheng:
Mitochondrial Epigenetic Changes Link to Increased Diabetes Risk and Early-Stage Prediabetes
Indicator. Oxidative Medicine and Cellular Longevity, Hindawi Publishing Corporation. Vol.
2016. Article ID 5290638. Available form: http://dx.doi.org/10.1155/2016/5290638

6. PRE-DIABETES the most neglected Medical Condition
• The whole system worried about Diabetes and to manage it & educating people to make aware
about it
• But we all forgetting the early asymptomatic, tough to diagnose, dangerous stage like Pre-
diabetes
• India is now capital in diabetes, but we all forget always that India is capital of pre-diabetes too
• Very less research papers and works on Pre-diabetes
• CCRH gave me this chance to research and they are also researching on pre-diabetes in 8 RRIs,
it’s a great thing, but we need more research and awareness about this
Dibaetes is not a Silent Killer, actually Pre-diabetes is the Silent Killer

7. • Primary objective
To explore the scope of Serially Successed and Diluted Drugs
(SSDD) [Homeopathic] in treating pre-hyperglycaemic
condition for prevention of diabetes mellitus.
• Secondary objective
To establish the usefulness individualistic approach of
classically selected homeopathic medicines to treat pre-
diabetic condition.
AIMS & OBJECTIVES

8. • Study design: Open label, observational,
prospective, single arm, non-randomized, non-
controlled study.
• Study duration: Six months
• Settings: Research study was conducted in
Midnapore town on the 30 patients (various
age, sex, body built, occupation, socioeconomic
status), suffering from pre-hyperglycaemic
condition, who attended the O.P.D. Of the
Midnapore Homoeopathic Medical College &
Hospital. Each patient was included after
taking Written Informed Consent From them.
METHODOLOGY

9. COLLECTION of PATIENTS

10. SCREENING TOOLS
• Indian diabetic risk score (IDRS) ≥ 60
• Glucometer test result: FBS 111-125 ± 25
and PPBS 140-199 ± 25
• Serum glucose test result: FBS 111-125
mg/dl and PPBS 140-199 mg/dl
• OGTT test result: also FBS 111-125 mg/dl
and PPBS 140-199 mg/dl

11. ELIGIBITY CRITERIA
• Age 10 years above & below 80 years and of both
sexes
• Impaired glucose regulation (two hrs. Oral glucose
tolerance test with 75 gm. Glucose load ≥140 mg/dl
and ≤ 199 mg/dl; fasting plasma glucose concentration
of ≥111mg/dl)or greater but ≤125 mg/dl
INCLUSION CRITERIA:

12. • Patients with diabetes mellitus with hypertension, and other
co-morbidities
• Psychiatric illness
• Cases with other systemic unevaluated or uncontrolled
diseases like cardiovascular, renal, gastro-intestinal,
endocrinal, gynaecological diseases etc. Or systemic
infections affecting quality of life or on other treatment
therapies
Exclusion criteria:

13. EXCLUSION CRITERIA Cont….
• Patients with any vital organ failure
• History of homeopathic treatment for any chronic
disease within last 6 months
• Self-reported immune-compromised states
• Alcohol and /or drug addiction or dependence
• Pregnant or lactating women
• Patients not giving consent

14. ASSESMENT PARAMETERS
Marked
improvement:
When the patient
is asymptomatic
and blood sugar
touches normal
level.
Moderate
improvement:
Symptomatic relief with
more than 50% reduction
in blood sugar level
persisting above normal
level or near to
borderline.
Mild
improvement:
Symptomatic relief with
less than 50% reduction in
blood sugar level but
above normal range.
No improvement:
No change in the patient
either symptomatically or
in the blood sugar level.
Aggravation:
Worsening of the
symptoms and or increase
in the blood sugar level.

15. With six months of treatment there
was 12.5 ±9.0 mg/dl (CI 9.15 to
15.8, p=0.0001) and 23.90 ±13.5
(ci: 18.9 to28.9; p=0.0001) in FBS
and PPBS levels respectively (table
2). Figure shows positive trend line
in reduction of blood sugar levels.
There was positive correlation
between IDRS score and fasting
blood sugar levels at baseline
(Pearson correlation coefficient
0.42; p= 0.02)
2.2
4.7
6.7
8.7
11.1
12.5
5.5
10.2
16.1
19.1
21.5
24.0
MONTH-1 MONTH-2 MONTH-3 MONTH-4 MONTH-5 MONTH-6Meanvalue
FBS PPBS

16. RESULTS…Cont.
From the study, it was found
that Marked Improvement
occurred in 33.33% cases,
Moderate Improvement was
observed in 23.33% cases,
Mild Improvement was seen in
26.67% cases and No
Improvement was evident in
16.67% cases. However none
of the cases got Worse (0%)
0
5
10
15
20
25
30
Male Female Total

17. FREQUENCY OF MEDICINES with RESULTS as per POTENCY
0
1
2
3
4
5
6
7
8
9
Frequency of the Appearance of Medicines
Lycopodium
Sulphur
Nat. Mur.
Phosphorus
Pulsatilla
Cal. Carb.
Nat. Sulph.
Psorinum
Sepia
Ars. Alb.
0
5
10
15
20
25
30
Centesimal
L.M.
Both
Total
Total No. of pts.
Pts. Imp.
Marked imp.
Moderate imp.
Mild imp.
No imp.
Worse

18. STRENGHTS & LIMITATIONS
Strengths of the study
• 30 patients screened from a wide
population through repeated
screening and through IDRS then
validated through OGTT
• May be the period was short but
the result is very valuable for
future on the perspective of very
less work in this field in the whole
world
Limitations of the study
• The study included only a small
group of 30 patients, so the
study was limited to a very small
circle.
• Study follow up was for officially
only 6 months

19. This study shows that classical homeopathic treatment
can bring an improvement in pre-diabetes/pre-
hyperglycaemic condition.

20. Planning for FUTURE STUDY
The present study although comes to an end, still it is incomplete unless further study is
done extensively on the following aspects. It should include-
• A wide range of patient with variety of region from whole India.
• A control group of study may be included to show the effectiveness of
homeopathy in a broader prospect.
• Genetic and Epigenetic analysis should be done
• HOMA test should be include
• All the outcomes should be measured in cell line and animal model.

21. GUIDE & MENTOR
Dr. Alok Kr. Ghosh
HOD, Dept. of Organon of Medicine,
MHMC&H, Midnapore
dralok_ghosh@yahoo.co.in
Dr. Kaushik D. Das
HOD, Dept. of Hom. Pharmacy,
MHMC&H, Midnapore
drkushikddas75@gmail.com

22.  Dr. C. K. Bhattacharjee, Ex-principal (acting) MHMC&H,
Midnapore
 Dr. N. C. Chatterjee, Guest Professor & Alumni
President, MHMC&H, Midnapore
 Dr. Praveen Oberai, Scientist, STSH Co-ordinator,
CCRH
 Dr. Chetna Lamba, Scientist, STSH Co-ordinator,
CCRH
 Dr. Varanasi Roja, Scientist, CCRH
 Mrs. Maya Padmanabhan, Statistical Assistant, CCRH
 Participating patients

23. SPECIAL THANKS…
 Dr. Raj K Manchanda, DG, CCRH
 Dr. Anil Khurana, Deputy DG, CCRH
 Dr. Chunilal Bhnuia, Principal Pathologist, Spandan Diagnostics, Midnapore
 Mr. M. M. Samnata, Teacher of Statistics, Midnapore Colligiate School
 Mr. Sabyasachi Maiti, Lecturer, Dept. of Statistics, K. D. College of Commerce, Midnapore
 Ethical Committee of MHMCH, Midnapore
 Dr. Srimanta Kumar Kunda, Ex-Senior Housstaff, MHMCH, Midnapore
 Dr. Snehasish Patra, Ex-student, MHMCH, Midnapore
 Mr. Arnab Sahoo
 Ms. Ruby Burnwal
 My Parents
 All others helped me to complete this project

24. THANKS FOR KIND LISTENING…..